Epidemiology of yeast species causing bloodstream infection in Tehran, Iran (2015-2017); superiority of 21-plex PCR over the Vitek 2 system for yeast identification

Kord, M.; Salehi, M.; Khodavaisy, S.; Hashemi, S.J.; Daie Ghazvini, R.; Rezaei, S.; Maleki, A.; Elmimoghaddam, A.; Alijani, N.; Abdollahi, A.; Doomanlou, M.; Ahmadikia, K.; Rashidi, N.; Pan, W.; Boekhout, T.; Arastehfar, A.

DOI
10.1099/jmm.0.001189

Publication date
2020

Document Version
Final published version

Published in
Journal of Medical Microbiology

License
CC BY-NC

Citation for published version (APA):
Kord, M., Salehi, M., Khodavaisy, S., Hashemi, S. J., Daie Ghazvini, R., Rezaei, S., Maleki, A., Elmimoghaddam, A., Alijani, N., Abdollahi, A., Doomanlou, M., Ahmadikia, K., Rashidi, N., Pan, W., Boekhout, T., & Arastehfar, A. (2020). Epidemiology of yeast species causing bloodstream infection in Tehran, Iran (2015-2017); superiority of 21-plex PCR over the Vitek 2 system for yeast identification. Journal of Medical Microbiology, 69(5), 712-720. https://doi.org/10.1099/jmm.0.001189
Epidemiology of yeast species causing bloodstream infection in Tehran, Iran (2015–2017); superiority of 21-plex PCR over the Vitek 2 system for yeast identification

Mohammad Kord1, Mohammadreza Salehi2, Sadegh Khodavaisy1*, Seyed Jamal Hashemi1, Roshanak Daie Ghazvini1, Sassan Rezaei1, Ayda Maleki1, Ahmad Elmimoghaddam1, Neda Alijani3, Mahsa Doomanlou4, Kazem Ahmadikia1, Niloofar Rashidi1, Weihua Pan5*, Teun Boekhout6,7 and Amir Arastehfar6,7

INTRODUCTION

Fungal bloodstream infections (BSIs) are a major cause of morbidity and mortality in critically ill patients [1, 2]. Candida species represent the fourth most common cause of BSIs in hospitalized patients in the USA [3]. It has been estimated that candidaemia is currently associated with a significant economic burden of USD $1.4 billion in the USA annually [4]. Depending on the yeast species, the mortality rate may vary from 30–85% [5]. Moreover, the increasing frequency of non-albicans Candida (NAC) species is not only associated with a higher mortality rate, but also a higher clinical rate of failure due to either acquired and/or intrinsic resistance to the limited number of antifungal drugs available to treat candidaemia [5, 6]. Since the antifungal susceptibility pattern

Received 21 January 2020; Accepted 24 March 2020; Published 05 May 2020

Author affiliations: 1Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; 2Department of Infectious Diseases and Tropical Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; 3Department of Infectious Diseases, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran; 4Department of Pathology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran; 5Medical Mycology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai 200003, PR China; 6Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands; 7Institute of Biodiversity and Ecosystem Dynamics (IBED), University of Amsterdam, Amsterdam, The Netherlands.

*Correspondence: Sadegh Khodavaisy, sadegh_7392008@yahoo.com; Weihua Pan, panweihua@smmu.edu.cn

Keywords: bloodstream infections; candidaemia; 21-plex PCR; Vitek 2.

Abbreviations: AMB, Amphotericin B; BSIs, Bloodstream infections; ICUs, Intensive care units; IDSA, Infectious Diseases Society of America; MALDI-TOF MS, Matrix-assisted Laser desorption/ionization time-of- flight mass spectrometry; NAC, Non-albicans Candida; SDA, Sabouraud dextrose agar.

© 2020 The Authors

This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial License.

Abstract

Introduction. Given the limited number of candidaemia studies in Iran, the profile of yeast species causing bloodstream infections (BSIs), especially in adults, remains limited. Although biochemical assays are widely used in developing countries, they produce erroneous results, especially for rare yeast species.

Aim. We aimed to assess the profile of yeast species causing BSIs and to compare the accuracy of the Vitek 2 system and 21-plex PCR.

Methodology. Yeast blood isolates were retrospectively collected from patients recruited from two tertiary care training hospitals in Tehran from 2015 to 2017. Relevant clinical data were mined. Identification was performed by automated Vitek 2, 21-plex PCR and sequencing of the internal transcribed spacer region (ITS1-5.8S-ITS2).

Results. In total, 137 yeast isolates were recovered from 107 patients. The overall all-cause 30-day mortality rate was 47.7%. Fluconazole was the most widely used systemic antifungal. Candida albicans (58/137, 42.3%), Candida glabrata (30/137, 21.9%), Candida parapsilosis sensu stricto (23/137, 16.8%), Candida tropicalis (10/137, 7.3%) and Pichia kudriavzevii (Candida krusei) (4/137, 2.9%) constituted almost 90% of the isolates and 10% of the species detected were rare yeast species (12/137; 8.7%). The 21-plex PCR method correctly identified 97.1% of the isolates, a higher percentage than the Vitek 2 showed (87.6%).

Conclusion. C. albicans was the main cause of yeast-derived fungaemia in this study. Future prospective studies are warranted to closely monitor the epidemiological landscape of yeast species causing BSIs in Iran. The superiority of 21-plex PCR over automated Vitek 2 indicates its potential clinical utility as an alternative identification tool use in developing countries.
varies depending on the yeast species, accurate species-level identification of yeasts causing BSIs is of high importance and may decrease the mortality rate of infected patients by guiding clinicians to administer proper antifungal treatment [5, 7].

Although sequencing of rDNA and other barcoding loci is considered to be the gold standard technique for the identification of yeast species, this technique is expensive and is not widely utilized in developing countries [8]. In contrast, time-consuming and/or less accurate phenotypic and biochemical assays, which can lead to the neglect of yeast species of high clinical importance, are widely used in developing countries [8–11]. For instance, a lack of appropriate identification tools resulted in an underestimation of Candida auris in developing countries [12]. In addition to manual biochemical assays, such as API 20C AUX, automated enzymatic/biochemical methods (e.g. VITEK YST Biochemical Card) are more comprehensive and sensitive and require a shorter turnaround time [13–15]. A recent study involving Asian countries showed the low popularity of PCR for the detection of fungal species directly from clinical samples [16], but this PCR with DNA samples obtained from pure cultures can be used to reliably identify a broad range of yeast species [8, 9, 17]. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is not available in Iran; therefore, most investigators identify causative agents of candidaemia using either phenotypic techniques [18–21] or PCR-RFLP assays [18, 22]. Recently, Arastehfar et al. developed a 21-plex PCR assay that can identify the causative agents of 95% of yeast-associated infections based on PCR product size in a stepwise manner [9]. Due to the limited number of systematic studies exploring the profile of yeast species causing BSIs in Iranian patients, we conducted the current study. Moreover, the accuracy of automated Vitek 2, one of the most popular automated biochemical assays in developing countries, was compared with that of 21-plex PCR.

**METHODS**

**Yeast isolates and growth conditions**

From 2015 to 2017, all patients admitted to two tertiary care training hospitals (Imam Khomeini Hospital complex and Shariati Hospital) affiliated with Tehran University of Medical Sciences, Tehran, Iran, were included in this study. We did not consider any exclusion criteria and yeast BSI was defined as occurring when a Candida/yeast species was isolated from at least one blood sample of a given patient. The mortality rate reported is all-cause and the 30-day mortality was defined as occurring when a yeast species was isolated from the first blood sample 30 days prior to death. Patients within the age categories of ≤16 years of age and >16 years of age were considered to be children and adults, respectively. Aerobic blood bottles were incubated in Bactec 9210 (Becton Dickinson, Spark, MD, USA) for 24h. Blood bottles without positive signal after 1 week's incubation in Bactec device were considered negative. One hundred microlitres of positive blood bottles was streaked onto both Sabouraud's dextrose agar (SDA) and Candida CHROMagar (CHROMagar, Paris, France) and incubated at 37°C for 24–48h. Colony morphology was assessed to differentiate blood samples concurrently infected with more than one yeast species. All yeast isolates were identified retrospectively.

This study was approved by the local ethical committees of Tehran University of Medical Science (IR.TUMS.SPH.REC.1398.324). Collection and presentation of the patients' general clinical data were waived by the local institutional review board and patient identities were anonymized through the use of code identifiers. Moreover, clinical data were presented in clusters and as a whole to further protect the patients' privacy.

**Vitek 2 system identification**

The automated Vitek 2 YST ID Card system (bioMérieux, Marcy-L’Étoile, France, database v.3.01) can identify 51 yeast species. The YST identification card is based on established biochemical methods, including newly developed substrates. According to the manufacturer’s instructions, cell suspensions were adjusted to a turbidity of 1.80–2.2 McFarland and all cards were incubated at 35.5±1.0°C for 18h [23]. The final profile results were compared with profiles from a database, and the identification of yeasts was based on the qualitative values of ‘excellent’, ‘very good’, ‘good’, ‘acceptable’, or ‘low discrimination’. Vitek 2 identifications were performed in the Imam Khomeini Hospital Complex, Tehran, Iran.

**DNA extraction and 21-plex PCR technique**

Yeast isolates were incubated for 48h on SDA medium containing chloramphenicol and subjected to a DNA extraction method as described previously [24]. Briefly, one full loop of yeast colonies (10µl) was transferred to 2ml screw-cap tubes containing 100µl glass beads, 300µl of lysis buffer (200 mM Tris-Hcl pH 8, 25 mM EDTA, 250 mM NaCl, 0.5% sodium dodecyl sulfate) and 300µl of phenol chloroform/isoamyl alcohol. The suspensions were vortexed for 2min and then centrifuged for 5min at 10000r.p.m. Subsequently, the supernatant was transferred to a new 1.5ml tube containing an equal volume of isopropanol, 300µl of chloroform and 0.1 vol of 3 M sodium acetate (pH 5.2). In the next step, the solutions were vortexed briefly and incubated at −20°C for 10min, followed by centrifugation for 15min at 12000r.p.m. The precipitant was washed with ice-cold 70% ethanol and centrifuged (15min at 12000r.p.m), the supernatant was removed and the pellet was air-dried and dissolved in 50µl of distilled water. Identification of yeasts with 21-plex PCR was performed in three multiplex PCRs as described previously [9]. Briefly, the first PCR reaction identifies the most prevalent Candida species [C. albicans, C. glabrata, Pichia kudriavzevii (C. kruisi), C. parapsilosis, C. tropicalis, C. dubliniensis and C. auris], the second PCR identifies rare Candida species [Diitina rugosa (C. rugosa), Clavispora lusitaniae (C. lusitaniae), Pichia norvegensis (C. norvegensis), Debaryomyces hansenii (C. famata), Yarrowia lipolytica (C. lipolytica), Meyerozyma guilliermondii (C. guilliermondii) and Klyveromyces marxianus (C. kefyr)] and the third multiplex PCR identifies the most clinically important basidiomycetous

---

**Kord et al., Journal of Medical Microbiology 2020;69:712–720**

---

Paris, France) and incubated at 37°C for 24–48h. Colony morphology was assessed to differentiate blood samples concurrently infected with more than one yeast species. All yeast isolates were identified retrospectively.

This study was approved by the local ethical committees of Tehran University of Medical Science (IR.TUMS.SPH.REC.1398.324). Collection and presentation of the patients' general clinical data were waived by the local institutional review board and patient identities were anonymized through the use of code identifiers. Moreover, clinical data were presented in clusters and as a whole to further protect the patients' privacy.

**Vitek 2 system identification**

The automated Vitek 2 YST ID Card system (bioMérieux, Marcy-L’Étoile, France, database v.3.01) can identify 51 yeast species. The YST identification card is based on established biochemical methods, including newly developed substrates. According to the manufacturer's instructions, cell suspensions were adjusted to a turbidity of 1.80–2.2 McFarland and all cards were incubated at 35.5±1.0°C for 18h [23]. The final profile results were compared with profiles from a database, and the identification of yeasts was based on the qualitative values of 'excellent,' 'very good,' 'good,' 'acceptable,' or 'low discrimination.' Vitek 2 identifications were performed in the Imam Khomeini Hospital Complex, Tehran, Iran.

**DNA extraction and 21-plex PCR technique**

Yeast isolates were incubated for 48h on SDA medium containing chloramphenicol and subjected to a DNA extraction method as described previously [24]. Briefly, one full loop of yeast colonies (10µl) was transferred to 2ml screw-cap tubes containing 100µl glass beads, 300µl of lysis buffer (200 mM Tris-Hcl pH 8, 25 mM EDTA, 250 mM NaCl, 0.5% sodium dodecyl sulfate) and 300µl of phenol chloroform/isoamyl alcohol. The suspensions were vortexed for 2min and then centrifuged for 5min at 10000r.p.m. Subsequently, the supernatant was transferred to a new 1.5ml tube containing an equal volume of isopropanol, 300µl of chloroform and 0.1 vol of 3 M sodium acetate (pH 5.2). In the next step, the solutions were vortexed briefly and incubated at −20°C for 10min, followed by centrifugation for 15min at 12000r.p.m. The precipitant was washed with ice-cold 70% ethanol and centrifuged (15min at 12000r.p.m), the supernatant was removed and the pellet was air-dried and dissolved in 50µl of distilled water. Identification of yeasts with 21-plex PCR was performed in three multiplex PCRs as described previously [9]. Briefly, the first PCR reaction identifies the most prevalent Candida species [C. albicans, C. glabrata, Pichia kudriavzevii (C. kruisi), C. parapsilosis, C. tropicalis, C. dubliniensis and C. auris], the second PCR identifies rare Candida species [Diitina rugosa (C. rugosa), Clavispora lusitaniae (C. lusitaniae), Pichia norvegensis (C. norvegensis), Debaryomyces hansenii (C. famata), Yarrowia lipolytica (C. lipolytica), Meyerozyma guilliermondii (C. guilliermondii) and Klyveromyces marxianus (C. kefyr)] and the third multiplex PCR identifies the most clinically important basidiomycetous
yeast species, namely *Trichosporon* spp., *Cryptococcus* spp., and *Rhodotorula mucilaginosa* and one ascomycota yeast, *Geotrichum* spp. (Fig. 1). All the primers included in the 21-plex PCR, including those for *C. auris*, were comprehensively evaluated using blinded test sets in our previous studies [9, 17]. PCR products and a 100 bp ladder were run on a 2% agarose gel (100 V, 60 min), stained with Gel Red (BioTium Corporation, USA) and visualized under UV light. Yeast species identification was achieved by discrimination of the fragment size of the PCR products (Fig. 2) [9].

### ITS sequencing

The internal transcribed spacer region (ITS1-5.8S-ITS2) was selected for sequencing according to a protocol described by Leaw et al. [25]. Bidirectional chain terminated Sanger sequencing using referenced primers was performed. The obtained sequences were searched using the NBLAST algorithm (https://blast.ncbi.nlm.nih.gov) and the identity of each strain was assigned accordingly. This experiment was carried out at the Department of Dermatology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, PR China.

### Statistical analysis

We used SPSS software v24 (SPSS, Inc. Chicago, IL, USA) and the Kappa test; we assessed the categorical agreement between the results obtained by the Vitek 2 system, 21-plex PCR and ITS sequencing.

### RESULTS

#### Clinical profiles

One hundred and thirty-seven episodes of yeast BSIs were diagnosed in 107 patients with ages ranging from 1 to 100 years old, with 92.5% of the patients (n=99) being ≥16 years of age. The majority of patients had a single episode of candidaemia (77/107; 72.0%), while 2 isolates were recovered from 30 patients (30/107; 28.0%). There was no difference in the acquisition of candidaemia from females (55/107; 51.4%) and males (52/107; 48.6%). Intensive care units (ICUs) contained the highest number of yeast BSI patients (55/107; 51.4%). Fever (70/107; 65.5%) and dyspnea (54/107; 50.5%) were recorded as the most observed clinical presentations. Pulmonary disease (33/107;
Fig. 2. 21-plex PCR identifies the species based on the PCR product size. The PCR product for each species has a distinct length. Adapted with permission from [9].
Table 1. Demographic and clinical characteristics and outcomes for patients with yeast BSIs in this study

| Variables                        | Candida albicans n (%) | Candida glabrata n (%) | Candida parapsilosis sensu stricto n (%) | C. tropicalis n (%) | C. krusei n (%) | C. parapsilosis s. marianus n (%) | Pichia kudriavzevii n (%) | Pichia dublinensis n (%) | Pichia marina n (%) | Clavispora lusitaniae n (%) | Meyerozyma guilliermondii n (%) | Kluyveromyces marxianus n (%) | Pichia norvegeniae n (%) | Cryptococcus neoformans n (%) | Trichosporon asteroides n (%) | Total n (%) |
|----------------------------------|------------------------|------------------------|------------------------------------------|--------------------|---------------|-----------------------------------|--------------------------|--------------------------|------------------------|-------------------------------|---------------------------------|-----------------------------|-----------------------------|---------------------------------|---------------------------|-------------|
| Age groups ≤16 years            | 3 (6.3)                | 1 (4.5)                | 4 (25.0)                                 | 0                  | 0             | 0                                 | 0                        | 0                        | 0                      | 0                             | 0                               | 0                           | 0                            | 0                               | 8/107 (7.5)                |            |
| >16 years                       | 45 (93.7)              | 21 (95.5)              | 12 (75.0)                                | 9 (100)            | 1 (100)       | 1 (100)                                          | 1 (09)                   | 1 (100)                  | 1 (100)               | 1 (100)                       | 1 (100)                        | 1 (100)                     | 1 (09)                      | 1 (09)                        | 99/107 (92.5)              |            |
| Total (%)                       | 48 (44.7)              | 22 (20.6)              | 16 (15.0)                                | 9 (8.4)            | 3 (2.8)       | 1 (09)                                           | 1 (09)                   | 2 (1.9)                  | 1 (09)                | 1 (09)                        | 1 (09)                         | 1 (09)                      | 1 (09)                      | 1 (09)                         | 107 (100)                 |            |
| Outcome                          |                        |                        |                                          |                    |               |                                                  |                          |                          |                       |                               |                                 |                             |                             |                                 |                              |            |
| Alive                            | 25 (52.1)              | 11 (50)                | 10 (62.5)                                | 4 (44.4)           | 1 (33.3)      | 1 (100)                                          | 1 (100)                  | 1 (50)                   | 0                      | 0                             | 0                               | 1 (100)                     | 0                           | 1 (100)                        | 56/107 (52.3)             |            |
| Died                             | 23 (47.9)              | 11 (50)                | 6 (37.5)                                 | 5 (55.6)           | 2 (66.7)      | 0                                                 | 0                        | 1 (50)                   | 1 (100)              | 1 (100)                       | 0                               | 1 (100)                     | 0                           | 1 (100)                        | 51/107 (47.7)             |            |
| Medication                       |                        |                        |                                          |                    |               |                                                  |                          |                          |                       |                               |                                 |                             |                             |                                 |                              |            |
| Recipient broad-spectrum antibiotics | 43 (89.5)              | 22 (100)               | 14 (87.5)                                | 7 (77.7)           | 3 (100)       | 1 (100)                                          | 1 (100)                  | 1 (50)                   | 1 (100)              | 1 (100)                       | 1 (100)                        | 1 (100)                     | 1 (100)                    | 1 (100)                        | 97/107 (90.7)             |            |
| fluconazole                      | 14 (29.1)              | 7 (31.8)               | 7 (43.7)                                 | 1 (11.1)           | 0             | 1 (100)                                          | 1 (100)                  | 0                        | 0                     | 0                             | 0                               | 0                           | 0                            | 0                               | 31/107 (29.0)             |            |
| caspofungin                      | 9 (18.7)               | 7 (31.8)               | 5 (31.2)                                 | 2 (22.2)           | 1 (33.3)      | 0                                                 | 0                        | 1 (50)                   | 1 (100)              | 0                             | 1 (100)                        | 0                           | 1 (100)                    | 1 (100)                        | 28/107 (26.2)             |            |
| amphotericin B                   | 8 (16.6)               | 4 (18.2)               | 7 (43.7)                                 | 1 (11.1)           | 0             | 0                                                 | 0                        | 0                       | 0                     | 0                             | 0                               | 0                           | 0                            | 0                               | 22/107 (20.6)             |            |
| voriconazole                     | 2 (4.1)                | 1 (4.5)                | 3 (18.7)                                 | 0                  | 0             | 0                                                 | 0                        | 0                       | 0                     | 0                             | 0                               | 0                           | 0                            | 0                               | 6/107 (5.6)               |            |
| corticosteroids                  | 10 (20.8)              | 7 (31.8)               | 3 (18.7)                                 | 2 (22.2)           | 0             | 1 (100)                                          | 0                        | 0                       | 0                     | 0                             | 0                               | 0                           | 0                            | 0                               | 23/107 (21.5)             |            |

Note that duplicate yeast isolates were recovered from 30 patients.
30.8%), solid tumours (32/107; 29.9%) and diabetes (31/107; 28.9%) were the principal underlying conditions detected in the patients. Broad-spectrum antibiotics and corticosteroids were used in 91% (97/107) and 21.5% (23/107) of the patients, respectively. Fluconazole (31/107; 29%) was the main antifungal prescribed to patients, followed by caspofungin (28/107; 26.2%), amphotericin B (AMB) (22/107, 20%) and voriconazole (6/107; 5.6%), whereas the rest of the patients were not treated with any antifungal drug (Table 1). Among the patients treated with systemic antifungals, 46.7% (50/107) received a single antifungal and 34.6% (37/107) received more than one antifungal. The overall 30-day mortality was 47.7% (51/107) and no difference in mortality rate was observed for patients infected with *C. albicans* (23/48; 47.9%) and NAC yeast species as a whole (28/59; 47.5%). Patients infected with *C. tropicalis* (5/9; 55.6%) and *C. glabrata* (11/22; 50%) showed the highest mortality rate (Table 1).

**Epidemiology and distribution of yeast species causing BSIs**

All yeast species isolated from the patients in this study were identified by ITS sequencing. *C. albicans* (58/137; 42.3%) was the most prevalent yeast species, and NAC species caused 56.2% of the yeast episodes (79/137) (Table 1). Among the main NAC species, *C. glabrata* (30/137; 21.9%) was the predominant species, followed by *C. parapsilosis* sensu stricto (23/137; 16.8%), *C. tropicalis* (10/137; 7.3%) and *P. kudriavzevii* (4/137; 2.9%) (Table 2). Almost 7.3% of the species detected (10/137) were rare *Candida* and 1.5% basidiomycetous yeasts (2/137), i.e. *Trichosporon* spp. and *Cryptococcus* spp. (Table 2). *C. parapsilosis* (4/8; 50%) was the most common species isolated from the bloodstream of children, followed by *C. albicans* (3/8; 37.5%), and *C. glabrata* (1/8; 12.5%) (Table 1). However, *C. albicans* (45/107; 42.1%) and *C. glabrata* (21/107; 19.6%) were the leading agents isolated from the bloodstream of adults (Table 1). In total, single and duplicate yeast isolates were recovered from 77 patients (77/107; 72%) and 30 patients (30/107; 28%), respectively. *C. albicans* (10/30; 33.3%), *C. glabrata* (8/30; 26.6%) and *C. parapsilosis* (7/30; 23.3%) had the highest number of duplicate isolates, followed by *P. kudriavzevii* (2/30; 6.6%) and *C. tropicalis*, *C. dubliniensis* and *K. marxianus* (1/30; 1.3% each).

**Comparative analysis of rDNA sequencing and 21-plex PCR**

One hundred and thirty-three yeast isolates (97.1%) were correctly identified by 21-plex PCR when compared to ITS sequencing (Table 2). All main *Candida* species, including *C. albicans*, *C. glabrata*, *C. parapsilosis*, *C. tropicalis* and *P. kudriavzevii*, were correctly identified by 21-plex PCR. Regarding the rare yeast species, *C. orthopsilosis* (*n*=2) and *T. asteroides* (*n*=1) were identified as *C. parapsilosis* and *T. asahii*, respectively, while *Cyberlindnera fabianii* (*n*=1) was not identified (Table 2). The categorical agreement for 21-plex PCR and ITS sequencing was 0.96.

![Table 2. Comparison of 21-plex PCR with Vitek 2 ID-YST system for identification of 137 yeasts isolated from blood samples](image)
Table 3. Misidentified isolates using 21-plex PCR and the Vitek 2 system compared to ITS sequencing

| Species               | Misidentified as                               | 21-plex PCR (n; %) | VITEK 2 system (n; %) |
|-----------------------|------------------------------------------------|--------------------|-----------------------|
| Candida albicans      | –                                               | –                  | Candida parapsilosis   |
|                       |                                                 | (1/58; 1.7)        | (1/1; 100)            |
|                       |                                                 | Candida ciferri     | (1/58; 1.7)           |
| Candida glabrata      | –                                               | Candida parapsilosis| (1/30; 3.3)           |
|                       |                                                 | Debaryomyces hansenii| (1/30; 3.3)           |
|                       |                                                 | (1/21; 4.7)        |                       |
| Candida parapsilosis  | –                                               | Cryptococcus laurentii| (1/10; 10)           |
|                       |                                                 | Debaryomyces hansenii| (1/21; 4.7)           |
| Candida tropicalis    | –                                               | Candida ciferri     | (1/2; 50)             |
| Pichia kudriavzevii   | –                                               | Yarrowia lipolytica| (1/4; 25)             |
| Candida orthopsilosis | Candida parapsilosis (2/2; 100)                 | Candida parapsilosis| (2/2; 100)            |
| Trichosporon asteroides| Trichosporon asahii (1/1; 100)                | –                  | –                     |
| Pichia norvegensis    | –                                               | Debaryomyces hansenii| (1/1; 100)           |
| Clavispora lusitaniae | –                                               | Candida ciferri     | (1/3; 33.3)           |
| Cyberlindnera fabianii| –                                               | Cryptococcus laurentii| (1/1; 100)           |
| Candida dubliniensis  | –                                               | Candida albicans    | (1/2; 50)             |

Comparative analysis of rDNA sequencing and the VITEK 2 system

Using the Vitek 2 system, 120 isolates (87.6%) were correctly identified, including 12 isolates that were identified with low scores (low discrimination). Almost 92% of the common *Candida* species were correctly identified and the misidentified cases all involved *Candida* species (*C. albicans*, *C. parapsilosis* and *C. glabrata*, two isolates each and *C. tropicalis* and *P. kudriavzevii* one isolate each) (Table 2). Among the rare *Candida* species isolated, six isolates (50%) were misidentified (Tables 2 and 3). For the basidiomyceteous yeasts, only *C. neoformans* was not identified, while *T. asteroides* was correctly identified (Tables 2 and 3). The categorical agreement between the Vitek 2 system (using database version 3.0.1) and ITS sequencing was 0.85.

DISCUSSION

In this study we compared the performance of Vitek 2 and 21-plex PCR for yeast species identification in an epidemiological study of yeast BSIs in Iran. In our epidemiological study, *C. albicans* was the most prevalent *Candida* species isolated; this result is consistent with the findings of a previous studies conducted in paediatric patients in Tehran [7, 26]. However, we found that *C. glabrata* was the second most prevalent *Candida* species, followed by *C. parapsilosis*, while Mirhendi et al. found that *C. parapsilosis* was the second most prevalent cause of candidaemia [26]. This is because they studied neonates and children, who are more prone to developing candidaemia due to *C. parapsilosis* [27]. In a systematic review, *C. parapsilosis* (30.8%) was the leading agent of candidaemia in Iran [28]. Although we found *C. parapsilosis* to be the leading cause of yeast-derived BSIs among children, the population size of children was small (only eight patients), and further studies are warranted to confirm this finding.

In general, the epidemiological profile observed in our study is closer to that of some Scandinavian countries [29–31], the USA [32] and Australia [33], where *C. albicans* and *C. glabrata* are the two leading causes of candidaemia. However, our epidemiological findings are different from those of India (where *C. tropicalis* is the leading cause) [34], Kuwait [35] and Southeast Asian [36] and Latin American countries [37], where *C. albicans* and *C. parapsilosis*/*C. tropicalis* are the two leading causes of candidaemia.

Although the Infectious Diseases Society of America (IDSA) recommends treating adult candidaemic patients with echinocandins [38], the high costs associated with these drugs discourage their use in the clinical settings of developing countries [34, 36, 39]. Therefore, most of our patients were treated with azoles (fluconazole and voriconazole) followed by caspofungin, which, along with the fact that antifungals were not used in almost 45% of our patients, may explain the all-cause 30-day mortality rate of 47.7% observed in our study. The overall mortality rate in our study is relatively similar to those observed in China (36.6%) [36], Spain (30.6%) [40] and France (41.5–56.9%) [41], but much lower than the high mortality rate of 72.2% reported in Brazil [42]. Although our isolate numbers are small, infection with *C. tropicalis* was associated with the highest mortality rate (55.6%) compared to other species, and this has been noted in other studies [43, 44]. The rise of azole-resistant *C. tropicalis* blood isolates in some studies is worrisome [34, 45, 46]. Unfortunately, we did not perform antifungal susceptibility testing, which is a major limitation of our study.

The Vitek 2 system could not identify 75% of emerging yeast species, including *C. lusitaniae*, *K. marxianus* and *P. norvegensis*, but these species were all correctly identified by 21-plex PCR. These species show variability in antifungal resistance and/or cause outbreaks in intensive care units, underscoring the importance of accurate species-level identification. For instance, it has been shown that *C. lusitaniae* can rapidly acquire multidrug resistance traits during the course of antifungal treatment with fluconazole, AMB and caspofungin [47]. *K. marxianus* can cause outbreaks, especially in leukaemic and hematological patients, with some isolates being resistant to AMB [48, 49]. *P. norvegensis*, a species close to *P. inconspicua*, is associated with azole resistance...
The 21-plex PCR showed a higher degree of accuracy for the yeast species included in this study compared with the Vitek 2 system. A previous study found a higher degree of accuracy when 21-plex PCR, as the first line identification tool, was used in combination with API 20C AUX for isolates that were not identified by 21-plex PCR [17]. 21-plex PCR showed superiority over the Vitek 2 system and the vast majority of rare yeasts and even a few isolates of the main Candida species were not correctly identified by the Vitek 2 system. Therefore, for laboratories lacking automated Vitek 2, MALDI-TOF, or biochemical identification assays, 21-plex PCR may be a useful technique for the identification of yeasts isolated from clinical samples. In addition, a previous Iranian study assessing candidaemia in paediatric patients showed that 95.7% of the species identified were in the target list of the 21-plex PCR [26]. Hence, 21-plex PCR can be used as a useful standalone technique in the routine laboratories of developing countries lacking specific and accurate identification tools, i.e. MALDI-TOF MS and Sanger sequencing, or expensive and time-consuming biochemical and phenotypic assays.

In this study, we showed the superiority of 21-plex PCR over the Vitek 2 system for the identification of yeast isolates. The application of 21-plex PCR assays for the identification of common and rare yeasts can reduce turnaround times and costs if applied in developing countries. The lack of detailed clinical data and antifungal susceptibility profiles are limitations of this study. Moreover, the database of our Vitek 2 system was old (v.3) and using newer versions may have resulted in a lower misidentification rate.

Funding information
This study was part of a PhD dissertation (grant No. 9511353003) and M.S. dissertation (grant No. 9711352002) supported by Tehran University of Medical Sciences. This study has been funded and supported by Tehran University of Medical Sciences (TUMS); Grant no. 2018Z×10101003); the National Natural Science Foundation of China (grant no. 99-1-99-46391; the National Health Department of China (grant no. 2020-63-382-394. 2). Arastehfar A, Wikkes BL, Ilkit M, Pincus DH, Daneshnia F et al. Identification of mycoses in developing countries. J Fungi 2019;5:90.

Arastehfar A, Fang W, Pan W, Lackner M, Liao W et al. Yeast panel multiple PCR for identification of clinically important yeast species: stepwise diagnostic strategy, useful for developing countries. Diagn Microbiol Infect Dis 2019;93:112–119.

Arastehfar A, Fang W, Al-Hatmi AMS, Afsarian MH, Daneshnia F et al. Unequivocal identification of an underestimated opportunistic yeast species, Cyrtocandida fabianii, and its close relatives using a dual-function PCR and literature review of published cases. Medical Mycology 2019;57:833–840.

Kathuria S, Singh PK, Sharma C, Prakash A, Masih A et al. Multidrug-Resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 2015;53:1823–1830.

Jeffery-Smith A, Taori SK, Schelzen S, Jeffery K, Johnson EM et al. Candida auris: a review of the literature. Clin Microbiol Rev 2018;31:e00029–00017.

Durán-Valle MT, Sanz-Rodríguez N, Muñoz-Paraiso C, Almagro-Moltó M, Gómez-Garcés JL. Identification of clinical yeasts by Vitek MS system compared with API ID 32 C. Med Mycol 2014;52:342–349.

Sanguinetti M, Porta R, Sali M, La Sorda M, Pecorini G et al. Evaluation of Vitek 2 and rapid yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. J Clin Microbiol 2007;45:1343–1346.

Keceli SA, Dündar D, Tamer ÖS. Comparison of Vitek matrix-assisted laser desorption/ionization time-of-flight mass spectrometry versus conventional methods in Candida identification. Mycopathologia 2016;181:67–73.

Chindamporn A, Chakrabarti A, Li R, Sun P-L, Tan B-H et al. Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia fungal Working Group (AFWG) initiative. Medical Mycology 2018;56:416–425.

Arastehfar A, Daneshnia F, Kord M, Roudabwy M, Zarrinfar H et al. Comparison of 21-plex PCR and API 20C aux, MALDI-TOF MS, and rDNA sequencing for a wide range of clinically isolated yeast species: improved identification by combining 21-plex PCR and API 20C aux as an alternative strategy for developing countries. Front Cell Infect Microbiol 2019;9:21.

Sadrossadati SZ, Ghahri M, Imani Fooladi AA, Sayyahfar S, Beyraghi S et al. Phenotypic and genotypic characterization of Candida species isolated from candidaemia in Iran. Curr Med Mycol 2018;4:14.

Razzaghi R, Momen-Heravi M, Erami M, Nazeri M. Candidemia in patients with prolonged fever in Kashan, Iran. Curr Med Mycol 2016;2:20.
20. Ahmadi NA, Davodi L. Candidemia after cardiac surgery in Tehran, Iran: a retrospective analysis of 424 cases at two medical centers. Alexandria J Med 2018;54:517–521.

21. Salehi M, Ghomi Z, Mirshahi R, Dehghan Manshadi SA, Rezahosseini O. Epidemiology and outcomes of candidemia in a referral center in Tehran. Caspian J Intern Med 2019;10:73.

22. Kafshdooz Jabari S, Chadeeganipour M, Ghahti M, Mohammadi R. Etiologic agents of Candidemia in pediatric immunocompromised patients. Iranian Journal of Pediatric Hematology and Oncology 2016;6:209–215.

23. Pincus DH. Microbial identification using the bioMérieux Vitek® 2 system. Encyclopedia of Rapid Microbiological Methods. Bethesda, MD: Parenteral Drug Association; 2006. pp. 1–32.

24. Sambrook J, Russell DW. Purification of nucleic acids by extraction with phenol:chloroform. CSH Protoc 2006;2006:pdv.prot4455.

25. Leaw SN, Chang HC, Sun HF, Barton R, Bouchra J-P et al. Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 2008;44:693–699.

26. Mirhendi H, Charsizadeh A, Eshaghi H, Nikmanesh B, Arendrup MC. Species distribution and antifungal susceptibility profile of Candida isolates from blood and other normally sterile foci from pediatric ICU patients in Tehran, Iran. Medical Mycology 2019;26.

27. Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014;20 Suppl 6:5–10.

28. Vaezi A, Fakhim H, Khodavaisy S, Alizadeh A, Nazeri M et al. Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis. J Mycol Med 2017;27:146–152.

29. Astvad KMT, Johansen HK, Reder BL, Rosenvinge FS, Knudsen JD et al. Update from a 12-year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern. J Clin Microbiol 2018;56:e01564–01517.

30. Lindberg E, Hammarsström H, Ataollahy N, Kondori N. Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia. Sci Rep 2019;9:3838.

31. Hestsveldt L, Gaustad P, Andersen CT, Haarr E, Hannula R et al. Twenty-Two years of candidaemia surveillance: results from a Norwegian national study. Clin Microbiol Infect 2015;21:938–945.

32. Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two us metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One 2015;10:e0120452.

33. Chapman B, Slavin M, Marriott D, Halliday C, Kidd S et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother 2017;72:1270–1108.

34. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H et al. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 2015;41:285–295.

35. Khan Z, Ahmad S, Al-Sweih N, Mokaddes E, Al-Banwan K et al. Changing trends in epidemiology and antifungal susceptibility patterns of six bloodstream Candida species isolates over a 12-year period in Kuwait. PLoS One 2019;14:e0216250.

36. Guo F, Yang Y, Kang Y, Zang B, Cui W et al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013;68:1660–1668.

37. Nucci M, Queiroz-Telles F, Alvarado-Mature T, Tiraboschi IN, Cortes J et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One 2013;8:e59373.

38. Pappas PG, Kaufmann CA, Andes DR, Clancy CJ, Marr KA et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases Society of America. Clin Infect Dis 2016;62:e393–e50.

39. Arastehfar A, Daneshnia F, Zomorodian K, Najafzadeh MJ, Khodavaisy S et al. Low level of antifungal resistance in Iranian isolates of Candida glabrata recovered from blood samples in a multicenter study from 2015 to 2018 and potential prognostic values of genotyping and sequencing of PDR1. Antimicrob Agents Chemother 2019;63:e02503–02518.

40. Puig-Asensio M, Padilla B, Garnacho-Montero J, Zaragoza O, Aguado JM et al. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clin Microbiol Infect 2014;20:0245–0254.

41. Lortholary O, Renaudat C, Sitbon K, Madec Y, Denœud-Ndam L et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 2014;40:1303–1312.

42. Doi AM, Pignatari ACC, Edmond MB, Marra AR, Camargo LFA et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian national surveillance program. PLoS One 2016;11:e0146909.

43. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis 2001;33:1676–1681.

44. Andes DR, Safdar N, Baddley JW, Alexander B, Brumble L et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated infection surveillance network (TRANSNET). Transpl Infect Dis 2016;18:921–931.

45. Chen P-Y, Chuang Y-C, Wu U-I, Sun H-Y, Wang J-T et al. Clonality of fluconazole-nonsusceptible Candida tropicalis in bloodstream infections, Taiwan, 2011–2017. Emerg Infect Dis 2019;25:1668–1675.

46. Arastehfar A, Daneshnia F, Hafez A, Khodavaisy S, Najafzadeh M-J et al. Antifungal susceptibility, genotyping, resistance mechanism, and clinical profile of Candida tropicalis blood isolates. Med Mycol 2019;4:1.

47. Azner SA, Giuliani S, Diiez M, Marchetti O, Sanglard D. Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother 2015;59:7715–7722.

48. Dufresne SF, Marr KA, Sydnon E, Staab JF, Karp JE et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol 2014;52:1830–1837.

49. Reuter CWM, Morgan MA, Bange F-C, Gunzer F, Eder M et al. Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neuorgenic leukemia patients. Clin Infect Dis 2005;41:1365–1366.

50. Sugita T, Takeo K, Ohkusu M, Virtudazo E, Takashima M et al. Fluconazole-Resistant pathogens Candida inconspicua and C. norvegensis: DNA sequence diversity of the rRNA intergenic spacer region, antifungal drug susceptibility, and extracellular enzyme production. Microbiol Immunol 2004;48:761–766.